Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.64 |
| ▸ | MGLL | Q99685 | 15/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510552 | 0.83 | TLR9 (0.64) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL3771981 | 0.83 | TLR9 (0.64) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL717690 | 0.82 | TLR9 (0.61) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL121404 | 0.79 | TLR9 (1.00) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL29377102 | 0.79 | TLR9 (1.00) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL718678 | 0.79 | TLR9 (0.57) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL1920666 | 0.78 | MAPK1 (0.40) | TLR9ALDH1A1 | |
| SCHEMBL7208771 | 0.77 | TLR9 (0.46) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL5174463 | 0.76 | TLR9 (0.44) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL30804538 | 0.75 | TLR9 (0.57) | TLR9MGLLFAAHHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3798231-A1 | CONJUGATED ANTI-CD38 ANTIBODIES | Takeda Pharmaceutical Company Limited (JP) | 2021-03-31 | — | — | EP | claimed |
| CN-104371124-A | Crosslinked polymer film based on sydnone click chemistry and preparation method thereof | UNIV EAST CHINA NORMAL | 2015-02-25 | — | — | CN | claimed |
| JP-4800614-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| JP-2006507232-A | — | — | 2006-03-02 | — | — | JP | claimed |
| EP-1534269-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004009082-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-01-29 | — | — | WO | claimed |
| EP-0157797-A1 | DETECTING AN IMMUNOLOGICAL REACTION WITH ACTIVATED RED BLOOD CELLS (ERYTHROCYTES) | IMMUCOR, INC. (US) | 1985-10-16 | — | — | EP | claimed |
| WO-1985001354-A1 | DETECTING AN IMMUNOLOGICAL REACTION WITH ACTIVATED RED BLOOD CELLS (ERYTHROCYTES) | IMMUCOR, INC. (US) | 1985-03-28 | — | — | WO | claimed |
| JP-57158783-A | — | — | None | — | — | JP | disclosed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037403-B2 | Compositions and methods for treating cancer with anti-CD123 immunotherapy | LENTIGEN TECHNOLOGY, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118345102-A | Compositions and methods for treating cancer with anti-CD 22 immunotherapy | 莱蒂恩技术公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113286607-B | Compositions and methods for treating cancer with anti-CD 19/CD22 immunotherapy | 莱蒂恩技术公司 | 2024-07-12 | — | — | CN | disclosed |
| US-4323647-A | IMMOBILIZED ENZYMES SEPARATION | UNIVERSITY OF MIAMI (US) | 1982-04-06 | — | — | US | disclosed |
| US-4276206-A | GENERALLY APPLICABLE METHOD OF MAKING IMMUNOSUPPRESSIVE AGENTS | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1981-06-30 | — | — | US | disclosed |
| US-4253995-A | PURIFICATION BY REACTING WITH BIOTIN AND SEPARATING ON AVIDIN COLUMN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| US-4253996-A | MALEIMIDE DERIVATIVE AS COUPLER FOR POLYPEPTIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| EP-0015059-A2 | Immunochemical conjugates: method and composition | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4220565-A | Immunochemical conjugates: method and composition | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | TLR9 1463/4885MGLL 1865/4885FAAH 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.